

## Cumulative Index 1990

### Volume 11

<b>March</b>	<b>DRUG-INDUCED PULMONARY DISEASE</b> , pages 1-194
<b>June</b>	<b>PULMONARY CONSIDERATIONS IN TRANSPLANTATION</b> , pages 195-362
<b>September</b>	<b>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</b> , pages 363-573
<b>December</b>	<b>ADULT RESPIRATORY DISTRESS SYNDROME</b> , pages 575-811

Note: Page numbers of complete issue and article titles are in boldface type.

Accelerated (cellular) rejection, definition, 270-271  
ACE inhibitors. See *Angiotensin-converting enzyme inhibitors*.

Acetylcysteine, for COPD, 473  
Acinus, lesions in, 395-400  
Acupuncture, for dyspnea in COPD, 436  
Acute chest pain syndrome, bleomycin-induced, 17  
Acute lung injury, alveolar fibrosis following, mechanisms, **657-672**  
anatomy, 659-662  
in ARDS, 634  
pneumonia and, 644  
definition, 657  
fibroproliferative response in, 659-668  
scoring system, 575-576  
 $\beta$ -Adrenergic agents, for cor pulmonale in COPD, 530-532  
 $\alpha$ -Adrenergic blockers, for cor pulmonale in COPD, 536-537  
 $\beta$ -Adrenoceptor agonists. See also  $\beta$ -Sympathomimetics.  
for COPD, 465-469  
theophylline and, for COPD, 467-468

Adult respiratory distress syndrome (ARDS), clinical disorders associated with, 576-579  
clinicopathologic correlations, 616  
cytokines in, 624-626  
death in, causes, 578, 581  
definition, 575-580  
endothelial injury in, 596-598  
fibrosis in, 601-604  
gas exchange abnormalities, 587  
heart-lung interaction, 691-714  
histologic changes, 797  
issue on, 575-580  
long-term sequelae, radiographic assessment, 744-745  
lung mechanics, **673-690**  
altered, implications, 684-687  
compliance, 676-678  
functional residual capacity, 684  
mean airway pressure, 680  
mean alveolar pressure, 680

measurement of, in pressure-controlled ventilation, 684  
monitoring of, 681-684  
resistance, 678-680  
lung mechanics in, peak cycling pressure, 680-681  
lung metabolic function in, **723-736**  
functional significance, 732-733  
future directions, 730-732  
macrophages in, 624  
management, ventilatory, **755-772**  
conventional methods, 755-759  
unconventional methods, 759-769  
mechanisms, 621-632  
multiple organ failure in, prevention, 639-641  
neutrophils in, 621-622, 627-628  
nosocomial pneumonia in, 641-656. See also *Pneumonia, nosocomial*.  
organ failure in, multiple, 581-591. See also *Multiple organ failure, in ARDS*.  
nonpulmonary, 579  
oxygen supply and consumption in, 715-722  
oxygen uptake-oxygen delivery relationships, 585  
pathoanatomy, 675-681  
pathogenesis, endotoxin in, 622-624  
following septic syndrome, 636-637  
PEEP in, 695-697  
postmortem arteriographic patterns, 608  
prognosis, 575-580  
pulmonary endothelial cell injury in, **723-736**  
pulmonary pathology, 593-619  
experimental models, 613-616  
exudative phase, 593-598  
fibrotic phase, 605  
localization of lesions, 612-613  
proliferative phase, 599-605  
pulmonary vasculature in, 606-612  
radiographic assessment, 737-754  
sepsis in, 576-579, 633-641. See also *Sepsis*.  
stages, radiographic assessment, 737-743  
survivors of, airflow resistance in, 792-793  
clinical evaluation, 790-791, 797-798

**Adult respiratory distress syndrome (ARDS) (Continued)**

- laboratory studies, 791-792
- pulmonary mechanics in, 792-793
- pulmonary volume measurement in, 793-794
- pulmonary sequelae, 789-800
- respiratory symptoms in, 790-791
- treatment, pharmacologic, 773-787
- ventricular function, 705-709

**Afterload, left ventricular, 702**

- right ventricular, 694-698

**Age, as factor in bleomycin-induced pulmonary toxicity, 2**

- as factor in COPD, 377
- as factor in lung transplantation, 212
- as factor in pulmonary sequelae following ARDS, 795

**Aging, panacinar emphysema associated with, 398**

**β-Agonists, for COPD, 366**

**Air-lung interface, anatomy, 658**

- granulation of air space, 663-667

**Air pollution, as factor in COPD, 383**

**Air space, granulation of, 663-667**

**Air space enlargement, classification, 396-397**

- emphysema and, 395-396
- and fibrosis, 398-399

**Airflow resistance, in ARDS survivors, 792-793**

**Airway, anatomy and physiology, 163-166**

- complications affecting, following lung transplantation, radiologic assessment, 341-343

**Airway disease, following bone marrow transplantation, 329**

**Airway obstruction, chronic, and bronchiolitis, 392-395**

- lesions occurring with, 389-390
- in COPD, 363

**Airway pressure, in ARDS, monitoring of, 682-683**

- positive, as factor in pulmonary sequelae following ARDS, 796

**Alcohol, as cause of hiccups, 184**

- as cause of respiratory depression, 178-179
- in COPD, 383

**Alkylating agents, pulmonary toxicity, 31-36**

**Allograft recipients, lung, infectious complications in, 291-308**

- bacterial pneumonia, 292-294
- CMV infection, 295-299
- mediastinitis, 294-295
- Pneumocystis carinii* infection, 299-301

**Allotransplantation, following lung transplantation, radiologic assessment, 336-339**

**lung, 269-278**

- chronic, and infection, 303-306
- clinical definition, 270-272
- in COPD patients, 553
- Epstein-Barr virus and, 303
- functional correlated, 273
- histologic evidence, 272-273
- immunologic parameters, 273-275
- immunopathogenesis, 269-270
- management, 275-276
- signs of, 266
- soluble IL-2R in, 274-275

**Almitrine, for COPD, 475**

- for cor pulmonale in COPD, 537-539

**Alpha-adrenergic blockers. See α-Adrenergic blockers.**

**Alpha-antitrypsins. See α<sub>1</sub>-Antitrypsins.**

**Alprazolam, for dyspnea in COPD, 431**

**Alveolar anatomy, 658-659**

**Aminoglycosides, for pneumonia in ARDS, 649**

**Amiodarone, as cause of lung injury, histopathology, 113-114**

- pharmacokinetics and metabolism of, relation to toxicity, 131-132

**Toxicity of, pulmonary, clinical aspects, 119-129**

- clinical manifestations, 120-122
- diagnostic evaluation, 123-125
- bronchoalveolar lavage, 123-124
- diagnostic evaluation of, gallium scintigraphy, 123
- direct, evidence for, 132-135
- indirect, evidence for, 135-136
- mechanisms, 131-138
- pathology, 124
- peripheral blood findings, 122
- physical findings, 122
- prognosis of patients with, 125-126
- pulmonary function testing, 122-123
- roentgenographic abnormalities, 122
- treatment, 126-127

**Angiotensin-converting enzyme (ACE) inhibitors, as cause of bronchospasm, 169-170**

**Anti-inflammatory agents, for COPD, 367**

- in prevention of ARDS and multiple organ failure, 639-640

**Antibiotics, for COPD, 473-474**

- for pneumonia in ARDS, 649
- pulmonary toxicity, 40-43

**Antibodies, preformed, in prevention of sepsis, 651**

**Anticholinergics, for COPD, 367, 469-471**

- for emphysema, 367

**Anticoagulation, in early postoperative management following lung transplantation, 265**

**Antidepressants, for COPD, 478-479**

**Antidiorphins, in prevention of ARDS and multiple organ failure, 640-641**

**Antidiotoxin antibodies, for ARDS, 780-781**

**Antidotoxins, in prevention of ARDS and multiple organ failure, 639**

**Antimetabolites, pulmonary toxicity, 36-40**

**Antimicrobial agents, in early postoperative management following lung transplantation, 262-263**

- for pneumonia in ARDS, 649

**Antirheumatic agents, as cause of pulmonary disease, 139-150**

**α<sub>1</sub>-Antitrypsins, in COPD, 476**

**Antitumor necrosis factor antibodies, for ARDS, 782-783**

**Antitussives, for COPD, 476-477**

**Anxiolytics, for COPD, 478**

**Arachidonic acid, role in bleomycin-induced lung fibrosis, 23-24**

**ARDS. See *Adult respiratory distress syndrome*.**

**Arterial blood gases, in long-term functional follow-up of lung transplant recipients, 351-352**

**Arthritis, rheumatoid, bronchiolitis and, penicillamine as cause of, 111**

- drug-induced, 110-113
- gold salt-induced, 112-113

**Aspergillosis, in the immunocompromised host, 60-61**

**Aspergillus, as cause of fungal infections in lung transplant recipients, 302**

- as cause of infection following bone marrow transplantation, 325

**Aspirin, as cause of bronchospasm, 167-169**

**Asthma, cromlyn for, 367**

- definition, 363-364
- diagnosis, 405-416
- pulmonary function testing, 407-410, 414-415

**Atelectasis, drug abuse as cause of, 155**

**Atopy, as factor in COPD, 383-384**

**Atropine, for COPD, 470**

**Azathioprine, in management of lung allograft rejection, 275**

- in management of lung transplant recipients, 280

pulmonary toxicity, 39–40  
*Aztreonam*, for pneumonia in ARDS, 649

**B**arotrauma, in ARDS, prevention, 686–687  
 radiographic assessment, 747–748

**Beta-agonists.** See  $\beta$ -Agonists.

**Beta-sympathomimetics.** See  $\beta_2$ -Sympathomimetics.

Bleomycin, as cause of acute chest pain syndrome, 17  
 as cause of hypersensitivity pneumonitis, 16–17  
 as cause of interstitial fibrosis, 2–14  
 mechanisms, 21–30  
 as cause of lung injury, 98–99  
 histopathology, 99  
 collagen synthesis following, 21–22  
 effect on pulmonary function tests, 14–16  
 routes of administration, 1  
 toxicity of, effects on organ systems, 1  
 pulmonary, 1–20, 69. See also *Pulmonary toxicity, bleomycin-induced*.

**B** $\beta$ -Blockers, as cause of bronchospasm, 166–167

Blood-lung interface, anatomy, 659, 661–662  
 following acute lung injury, 667–668

Bone marrow transplantation, immunosuppressive agents used in, 321–322  
 pulmonary complications following, 321–332  
 acute, 324–327  
 chronic, 327–329  
 diagnostic approach, 329–330  
 pulmonary complications in, 58  
 survival statistics, 324

Borg category scale, 438

Breathlessness. See *Dyspnea*.

Bronchi, lesions of, 390–391

Bronchiectasis, heroin abuse as cause of, 156

Bronchiolitis, chronic airway obstruction and, 392–395  
 obliterative, following heart-lung transplantation, 309–321  
 clinical manifestations, 310–315  
 definition, 309–310  
 etiology, 317–318  
 pathogenesis, 318–320  
 prognosis, 317  
 pulmonary function alterations, 313  
 treatment, 315–317  
 respiratory, 395

Bronchiolitis obliterans, following lung transplantation, 339–341  
 gold salt-induced, 143–144  
 penicillamine-associated, 141–142  
 penicillamine-induced, 111–112

Bronchitis, asthmatic, definition, 364  
 chronic, bronchial wall thickening in, 391  
 definition, 364  
 diagnosis, 405–416  
 pulmonary function testing, 407–410  
 inflammation in, 391  
 mucous gland enlargement in, 390–391  
 smooth muscle hyperplasia in, 391

lymphocytic, following bone marrow transplantation, 327

Bronchoalveolar lavage, for determining infection following lung transplantation, 271–272, 273–274  
 in evaluation of amiodarone pulmonary toxicity, 123–124

Bronchodilators, for COPD, 425

Bronchospasm, drug-induced, 163–175  
 $\beta$ -blockers, 166–167  
 ACE inhibitors, 169–170

aspirin, 167–169  
 cholinesterase inhibitors, 167  
 inhalational agents, 171–172  
 neuromuscular blocking agents, 172  
 Bruce protocol, modified, in long-term functional follow-up of lung transplant recipients, 356

Busulfan, pulmonary toxicity, 35–36  
 uses, 35

**C**alcium channel blockers, as cause of neuromuscular transmission impairment, 180–181

*Candida albicans*, as cause of fungal infections in lung transplant recipients, 301–302

Candidiasis, in the immunocompromised host, 61

Cannulas, reservoir, for oxygen delivery, 515

Captopril, for cor pulmonale in COPD, 537

Cardiovascular failure, in ARDS, 581–582

Carmustine, pulmonary toxicity, 45–47

Catheters, pulmonary infarction caused by, in ARDS, radiographic assessment, 751–752  
 transtracheal, for oxygen delivery, 514–515

Central nervous system (CNS) failure, in ARDS, 583

Chemotherapeutic agents, and bleomycin, as cause of pulmonary toxicity, 6

Chest pain, acute, bleomycin-induced, 17

Chlorambucil, pulmonary toxicity, 36

Chlorozotocin, pulmonary toxicity, 48

Cholinesterase inhibitors, as cause of bronchospasm, 164

Chronic obstructive pulmonary disease (COPD), acute respiratory failure in, oxygen therapy for, 508–509  
 age as factor in, 377

asthma in, 363–364

bronchitis in, 364

cor pulmonale in, 523–545. See also *Pulmonary heart disease, in COPD*

course and prognosis, 367

definitions, 363–373

diagnosis, 405–416. See also specific diagnostic tests.

disease states leading to, 365–366

dyspnea in, 417–445  
 acupuncture for, 436  
 evaluation, 423–425  
 emphysema in, 364–365  
 epidemiology, 375–387  
 ethnic status as factor in, 377–379  
 exercise reconditioning in, 433–435  
 features, 363  
 gender differences in, 376–377  
 hyperinflation in diagnosis of, 367–371  
 inspiratory muscle training in, 431–433  
 issue on, 363–369

lung transplantation for, 547–554

medical problems associated with, and dyspnea, 422–423

morbidity in, 375–379

mortality in, 379–380

nutritional assessment and support in, 487–504. See also *Nutrition, in COPD*

oxygen for, 429–430  
 in the home, long-term, 505–521

oxygen transport and mixed venous oxygenation in, 525–529

pathophysiology, 389–403  
 and dyspnea, 420–421

prognosis, 555–569  
 comparison of studies, 557–567  
 problems related to, 555  
 survival curves, 564–567

Chronic obstructive pulmonary disease (COPD)  
*(Continued)*  
 survival factors, 556-564  
 psychologic and psychosocial therapy for, 436  
 pulmonary hypertension in, etiology and natural history, 524-525  
 pulmonary rehabilitation in, 447-460, 510-511. See also *Pulmonary rehabilitation, for COPD*.  
 pursed lips breathing in, 433  
 risk factors, 380-384  
 risk models, 384  
 role of cardiac output response in adaptation to, 529  
 single lung transplantation in, 196  
 treatment, 425-436  
   antitussives, 476-477  
   long-term, 479-482  
   oxygen, 474-475  
   pharmacologic, 461-487  
     antibiotics, 473-474  
     anticholinergics, 469-471  
     corticosteroids, 471-472  
     diuretics, 476  
     mucokinetic agents, 472-473  
     psychoactive drugs, 477-479  
     respiratory stimulants, 475  
     sympathomimetics, 465-469  
     theophylline, 461-465  
   systematic, responses, 365-367  
 undernutrition in, magnitude of, 488  
   significance, 487-488  
**CMV.** See *Cytomegalovirus infection*.  
**Cocaine abuse.** pulmonary complications caused by, 156-158  
**Colchicine.** as cause of pulmonary disease, 147  
**Collagen.** synthesis of, following bleomycin treatment, 21-22  
**Companion.** for oxygen delivery, 515-516  
**Compliance.** in left ventricular function, 699-702  
**Computed tomography (CT).** in drug-induced pulmonary disease, 88-91  
   in emphysema, 412-414  
   in interstitial fibrosis secondary to bleomycin-induced toxicity, 9-11  
**Contrast media.** as cause of bronchospasm, 170  
**COPD.** See *Chronic obstructive pulmonary disease*.  
**Cor pulmonale.** See *Pulmonary heart disease*.  
**Corticosteroids.** for amiodarone pulmonary toxicity, 127  
   for ARDS, 774-776  
   for COPD, 471-472  
   as factor in lung transplantation, 213  
   for radiation-induced lung injury, 69-70  
**Cough.** drug-induced, 163-175  
**Cromolyn.** for asthma, 367  
   for COPD, 475  
**Cryptococcus neoformans** infection, in the immunocompromised host, 61  
**Cryptococcus neoformans**, as cause of fungal infections in lung transplant recipients, 302  
**CT.** See *Computed tomography*.  
**Cyclophosphamide.** pulmonary toxicity of, 31-35  
   and lung injury, 101-102  
    clinical features, 33-34  
    histopathology, 101-102  
    mechanisms, 31-33  
    risk factors, 34  
**Cyclosporine.** in heart-lung transplantation, 235-236  
   in lung allograft rejection, 275  
   in management of lung transplant recipients, 263, 279-280  
   with cystic fibrosis, 285

side effects, 280-283  
   gastric atony, 282  
   hepatotoxicity, 281  
   hyperkalemia, 283  
   hypertension, 281  
   hypertrichosis and gingival hyperplasia, 282  
   hypomagnesemia, 282-283  
   nephrotoxicity, 281  
   neurologic manifestations, 282  
   photosensitivity/skin lesions, 283  
 in management of lung transplant recipients with COPD, 551-553  
**Cystic fibrosis.** lung transplantation recipients with, post-operative management, 284-285  
**Cytochrome P<sub>450</sub>** enzymes, role in oxygen toxicity, 76  
**Cytokines,** in regulation of inflammation, 624-626  
**Cytomegalovirus (CMV) infection,** following bone marrow transplantation, 325-326, 328  
   following heart-lung transplantation, 243-244  
 following lung transplantation, 263, 295-299  
   clinical manifestations, 297  
   occurrence in postoperative course, 295-296  
   pneumonia from, 297-298  
   prevalence, 296-297  
   prevention, 296-297  
   treatment and outcome, 298-299  
 in the immunocompromised host, 59-60  
**Cytosine arabinoside,** pulmonary toxicity, 38-39  
**Cytotoxic agents,** major tissue reactions with, 95-98  
   pulmonary toxicity of, 31-34. See also specific agents, e.g., *Cyclophosphamide*.  
  
**Decontamination, selective,** in prevention of pneumonia, 651  
**Delayed (cellular) rejection,** definition, 271  
**Dexamethasone,** for ARDS, 775-776  
**Diazepam,** for dyspnea in COPD, 430-431  
**Digitalis,** for cor pulmonale in COPD, 529-530  
**Digoxin,** for COPD, 475-476  
**Dihydrocodeine,** for dyspnea in COPD, 431  
**Diuretics,** for COPD, 476  
**Donor lung,** and early thoracic infections, 219-220  
   preservation techniques, 223-225  
   procurement of, 220-222  
**Donors,** in lung transplantation. See *Lung transplantation, donors in*  
   for COPD patients, 548  
**DO2S system,** for oxygen delivery, 516  
**Drug abuse,** pulmonary reactions, 151-162  
   foreign body granulomatosis, 153-155  
   infectious complications, 151-152  
   pleural abnormalities, 153  
   pneumomediastinum, 152-153  
   pneumothorax, 152-153  
   pulmonary bullae and atelectasis, 155  
   pulmonary hypertension, 153-155  
**Drugs,** adverse effects of, on respiratory muscles, 177-189  
**Dyspnea,** in COPD, 417-445  
   treatment, 425-436  
   effect of posture on, 436  
   evaluation, 423-425  
   intermittent negative pressure ventilation for, 436  
   medical problems associated with COPD as cause of, 422-423  
   oxygen for, 429-430  
   pathophysiology of COPD and, 420-421  
   physiologic mechanisms, 417-420  
     hypercapnia, 420  
     hypoxemia, 420

increase in ventilatory drive, 418–419  
 length-tension inappropriateness, 419  
 pulmonary arterial or venous hypertension, 419–420  
 psychosocial variables related to, 421–422  
 pulmonary function testing, 436  
 pursed lips breathing in, 433  
 surgery for, 436  
**Dyspnea index, baseline, 440–441**  
 transition, 442–443

**Edema, hydrostatic versus increased-permeability, in**  
 ARDS, radiographic assessment, 745–746  
 pulmonary. See *Pulmonary edema*.  
**Emphysema, and airspace enlargement, 395–396**  
 anticholinergics for, 367  
 cartilage atrophy in, 391  
 clinical correlations and diagnosis, 399–400  
 definition, 364–365, 395–396  
 diagnosis, 405–416  
 CT in, 412–414  
 hyperinflation in, 367–371  
 pulmonary function testing, 407–410  
 malnourished patients with, 435–436  
 morphology, 397–399  
 single lung transplantation in, 228  
 transplant consideration for patients with, 547–548  
**Endothelial cell injury, pulmonary, in ARDS, 723–736**  
 von Willebrand factor antigen as indicator of, 724, 725  
**Endothelium, injury to, in ARDS, 596–598**  
 pulmonary, metabolic activity of, 724–730  
**Endotoxin, in ARDS, 622–624**  
**Endotracheal intubation, as cause of pneumonia in ARDS, 645**  
**Eosinophils, pulmonary, as cause of lung injury, 104–105**  
 role in inflammatory process associated with bleomycin-induced lung fibrosis, 27  
**Epstein-Barr virus infections, as cause of fungal infections in lung transplant recipients, 302–303**  
**Ethchlorvynol abuse, pulmonary complications caused by, 158**  
**Ethnic groups, COPD in, 377–379**  
**Euro-Collins solution, for pulmonary flush, modified, 221**  
**Exercise, following lung transplantation, 252, 254**  
 oxygen therapy during, in COPD patients, 509  
**Exercise training, in COPD, 433–435**

**Fatigue, drug-induced, 185**  
**Fibrosis, airspace enlargement and, 398–399**  
 alveolar, following acute lung injury, 657–672  
 in ARDS, 601–604  
 bleomycin-induced, expression of gene products following, 24–25  
 future research, 27  
 inflammatory cell changes in, 25–27  
 mechanisms, 21–30  
 role of arachidonic acid products in, 23–24  
 role of oxygen intermediates/antioxidant systems, 22–23  
**Interstitial, bleomycin-induced, 2–14**  
 clinical presentation, 8–9  
 course, 13–14  
 diagnosis, 12–13  
 factors influencing, 2–6  
 mortality, 14  
 outcome, 13–14

pathology, 6–8  
 radiographic manifestations, 9–12  
 idiopathic, in the immunocompromised host, 61–62  
 risk factors, 4  
 radiation, 68  
**Flush prostaglandin Euro-Collins solution technique, for procurement of donor lungs, 221–225**  
**Foreign body granulomatosis, drug abuse as cause of, 153–155**  
**Functional residual capacity, in ARDS, 684**  
**Fungus(i), in lung allograft recipients, 301–303**

**Gallium-67 lung scintigraphy, in evaluation of amiodarone pulmonary toxicity, 123**  
**Galium scans, in pulmonary interstitial fibrosis secondary to bleomycin-induced toxicity, 11–12**  
**Ganciclovir, and hyperimmune globulin, for prevention of *Pneumocystis carinii* infection, 287**  
**Gastric emptying, side effects, 282**  
**Gastrointestinal failure, in ARDS, 582**  
**Genes, expression of, following bleomycin-induced lung fibrosis, 24–25**  
**Genetics, as factor in COPD, 382–383**  
**Gold salts, as cause of pulmonary disease, 142–144**  
 as cause of rheumatoid lung, 112–113  
**Graft failure, primary, histology, 222–223**  
**Guillain-Barré syndrome, respiratory muscle paresis or paralysis in, 179**

**Heart-lung interaction, in ARDS, 691–714**  
**Heart-lung transplantation, 235–246**  
 allograft rejection following, management, 275–276  
 arterial blood gases following, 351–352  
 for COPD, procedure, 548–549  
 donor selection in, 237  
 history, 235–236  
 immunosuppression following, 242  
 indications, 209–210  
 late results and complications, 244–245  
 obliterative bronchiolitis following, 309–321. See also *Bronchiolitis, obliterative*.  
 organ preservation in, 239–240  
 pulmonary complications following, 242–244  
 implantation response, 242  
 infection, 243–244  
 rejection, 242–243  
 pulmonary function testing following, 273, 350  
 recipient management, 240–244  
 recipient selection, 236–237  
 6-minute walk test following, 354  
 stage I exercise test following, 356  
 technique, 237–240  
 procurement of donor organs, 237–239  
 removal of diseased heart and lungs and donor organ implantation, 239

**Hematologic failure, in ARDS, 583**  
**Hemorrhage, alveolar, following bone marrow transplantation, 326–327**  
 following double lung transplantation, re-exploration for, 232

**Heroin abuse, as cause of bronchiectasis, 155**  
 as cause of pulmonary edema, 155–156

**Hiccups, drug-induced, 184–185**

**Humoral (hyperacute) rejection, definition, 270**

**Hydralazines, for cor pulmonale in COPD, 534**

Hydrocarbons, inhalation of, pulmonary complications caused by, 159

Hypercholesterolemia, following lung transplantation, 285-286

Hyperimmune globulin, and ganciclovir, in prevention of *Pneumocystis carinii* infection, 287

Hyperinflation, in COPD, 367-371

Hyperkalemia, cyclosporine and, following lung transplantation, 283

Hyperplasia, gingival, cyclosporine and, following lung transplantation, 282

Hyperplastic smooth muscle, in chronic bronchitis, 391

Hypertension, cyclosporine and, following lung transplantation, 281

dyspnea related to, 419-420

pulmonary, drug abuse as cause of, 153-155

Hyperthermia, malignant, drug-induced, 184

Hyperthermic cardiopulmonary bypass, for procurement of donor lungs, 220

Hypertrichosis, cyclosporine and, following lung transplantation, 282

Hypnotics, for COPD, 478-479

Hypomagnesemia, cyclosporine and, following lung transplantation, 282-283

Hypotension, following double lung transplantation, 232

Hypoventilation, central, drug-induced, 177-179

Hypoxemia, in early postoperative management following lung transplantation, differential diagnosis, 266-267

Hypoxia, tissue, in ARDS, 716-720

Ibuprofen, for ARDS, 782

IL-2R, soluble, serial determinations of, in clinical diagnosis of rejection, 274-275

Immunocompetence, impaired, conditions predisposing to, 56

- diffuse pulmonary infiltrates in, 55-64
- and drug-induced pulmonary disease, 58-59
- and idiopathic interstitial fibrosis, 61-62
- and infection, 59-61
- and pulmonary disease, unusual complications, 62
- and recurrence of underlying pulmonary process, 57-58
- and "unrelated" disease, 62

Immunosuppression, following heart-lung transplantation, 242

- following lung transplantation, in COPD patients, 551-553
- early postoperative management, 263

Immunosuppressive agents, in management of bone marrow transplant recipients, pulmonary complications caused by, 321-322

- in management of lung transplant recipients, 279-280

Infection, ARDS-associated, 576-579

- and chronic allograft rejection, 303-306
- extrapulmonary, as cause of pneumonia in ARDS, 644-645
- as factor in pulmonary sequelae following ARDS, 796-797
- following heart-lung transplantation, 243-244
- following lung transplantation, prevention, 286
- lung, associated with donor lung, 219-220
- in the immunocompromised host, 59-61
- fungus, 60-61

Inflammation, in chronic bronchitis, 391

- regulation of, cytokines in, 624-626

Inflation-deflation cycle, of lungs, 674-675

Inhalational agents, as cause of bronchospasm, 171-172

Inspiratory muscle training, in COPD, 431-433

Intermittent negative pressure ventilation, for dyspnea, 436

Interstitial, anatomy, 658-660

Iodide, for COPD, 472

Ipratropium, for COPD, 470-471

Kidney failure, in ARDS, 582

- bleomycin-induced, and risk of pulmonary toxicity, 5-6

Kidney function, and fluid balance, in early postoperative management following lung transplantation, 261-262

*Legionella pneumophila*, as cause of bacterial pneumonia following bone marrow transplantation, 324

*Legionella pneumophila* infection, in the immunocompromised host, 59

Leukemia, pulmonary complications, 57-58

Liver failure, in ARDS, 582-583

Lomustine, pulmonary toxicity, 48

Lung, infection of, in the immunocompromised host, 59-61

- injury, metabolic function of, 726-730
- mechanics of, in ARDS, 673-690. See also *Adult respiratory distress syndrome, lung mechanics*.
- normal, 673-675
- metabolic activity of, 724-726
- pathology, in ARDS, 593-619

Lung injury, amiodarone-induced, histopathology, 113-114

- azathioprine-induced, 39-40
- bleomycin-induced, 98-99
- busulfan-induced, 35-36
- carmustine-induced, 45-47
- chlorambucil-induced, 36
- chlorozotocin-induced, 48-49
- cyclophosphamide-induced, 31-35, 101-102
- cytosine arabinoside-induced, 38-39
- drug-induced, antirheumatic agents as cause of, 139-150
- histopathology, 95-117
- lomustine-induced, 48
- melphalan-induced, 36
- 6-mercaptopurine-induced, 39-40
- methotrexate-induced, 36-39, 99-100
- mitomycin-induced, 40-43, 102-103
- neocarzinostatin-induced, 43
- oxygen-induced, 73-86
- biochemical basis of, 73-76. See also *Oxygen toxicity, biochemical basis of*
- pathology, 78-80
- pharmacologic aspects, 76-78
- physiologic manifestations, 80-82
- procarbazine-induced, 49
- radiation-induced, 65-71
- clinical presentation, 67-69
- radiation fibrosis, 68
- radiation pneumonitis, 67-68
- diagnosis, 69
- histopathology, 66-67
- pathogenesis, 65-67
- potentiation of toxicity, 69
- radiobiology, 65-66
- treatment, 69-70
- semustine-induced, 48
- septic, pathology, 636
- stages, radiographic assessment, 737-743

teniposide-induced, 49  
 Lung transplantation, airway complications following, radiologic assessment, 341-343  
 allograft rejection following, 336-339  
 diagnosis and management, 269-278. See also *Allograft rejection, lung*  
 applicant assessment, psychosocial, 247-249  
 stress as factor in, 248  
 bronchiolitis obliterans following, radiologic assessment, 339-341  
 for COPD, 547-554  
 donor criteria, 548  
 immunosuppression following, treatment, 551-553  
 patient selection, 547-548  
 procedures, 548-551  
 rejection following, 553  
 donor lung in, and early thoracic infections, 219-220  
 preservation techniques, 223-225  
 procurement of, 220-222  
 donors in, 217-226  
 future directions, 225  
 general maintenance, 217-218  
 selection procedure, 218-219  
 double, 227-233  
 arterial blood gases following, 351  
 clinical experience, 230  
 complications, 230-232  
 for COPD, procedure, 549-550  
 donor selection for, 228  
 hemorrhage following, re-exploration for, 232  
 history, 227-228  
 hypotension following, 232  
 indications, 209  
 modified Bruce protocol following, 356  
 pulmonary function tests following, 350  
 recipients for, 228  
 sepsis following, 232-233  
 6-minute walk test following, 352-354  
 stage I exercise test following, 356  
 technique, 229-230  
 functional outcome and life satisfaction following, 254-256  
 issue on, 195-358  
 lymphoproliferative disorders following, radiologic assessment, 342, 344  
 postoperative management, 279-290  
 azathioprine, 280  
 cyclosporine, 279-280  
 side effects, 280-283  
 in cystic fibrosis patients, 284-285  
 diaphragmatic paralysis, 288  
 drug interactions, 283-284  
 early, 259-267  
 airway, 265-266  
 anticoagulation, 265  
 antimicrobial therapy, 262-263  
 hemodynamic, 261  
 hypoxemia, 266  
 immunosuppression, 263  
 nutrition, 262  
 renal function and fluid balance, 261-262  
 ventilatory, 263-265  
 in the home, 288-289  
 immunosuppressive agents, 279-280  
 nutritional aspects, 285-286  
 prednisone, 280  
 prevention of lethal infections, 286-287  
 stents in, 287-288  
 preoperative assessment, 207-215

formal, 214  
 psychiatric, psychosocial, and rehabilitative aspects, 247-257  
 psychiatric and psychosocial aspects, in postoperative phase, 252-254  
 in preoperative phase, 249-251  
 pulmonary and cardiac changes following, radiologic assessment, 342-345  
 pulmonary nodular disease following, radiologic assessment, 345  
 radiologic assessment following, 333-346  
 recipients of, infectious complications in, 291-308. See also *Allograft recipients, lung, infectious complications in*  
 in Toronto Lung Transplant Group, arterial blood gases, 351-352  
 long-term functional follow-up of, 347-358  
 modified Bruce protocol, 356  
 mortality data, 348-349  
 pulmonary function tests, 349-350  
 6-minute walk test, 352-354  
 stage I exercise test, 354-356  
 rehabilitative aspects, in postoperative phase, 254  
 in preoperative phase, 251-252  
 reimplantation response following, radiologic assessment, 333-336  
 selection criteria, 210-214  
 medical, 210-213  
 psychosocial, 213-214  
 single, anesthetic considerations, 196-198  
 arterial blood gases following, 351  
 choice of side in, 196  
 contraindications, 195-196  
 for COPD, procedure, 550-551  
 in emphysema patients, 228  
 harvest for, technique, 196  
 indications, 208-209  
 modified Bruce protocol following, 356  
 pulmonary function tests following, 349-350  
 quantitative perfusion lung scan following, 356  
 6-minute walk test following, 352  
 stage I exercise test following, 354-355  
 surgical aspects, 195-205  
 technique, 198-203  
 Lymphocytes, role in inflammatory process associated with bleomycin-induced lung fibrosis, 26-27  
 Lymphoma, following lung transplantation, radiologic assessment, 342  
 pulmonary complications, 57  
 Lymphoproliferative disease, as cause of fungal infections in lung transplant recipients, 303

Macrophages, in ARDS, 624  
 role in inflammatory process associated with bleomycin-induced lung fibrosis, 26  
 Magnetic resonance imaging (MRI), in COPD, 414  
 in morphologic diagnosis of drug-induced pulmonary disease, 92-93  
 Magnetic resonance spectroscopy, in morphologic diagnosis of drug-induced pulmonary disease, 92-93  
 Malnourishment, COPD-related, 435-436  
 Malnutrition, as factor in pneumonia, 650  
 following lung transplantation, in cystic fibrosis patients, 284-285  
 Marijuana abuse, pulmonary complications caused by, 158-159  
 Mediastinitis, in lung allograft recipients, 294-295  
 Medical Research Council Dyspnea Scale, modified, 439

Melphalan, pulmonary toxicity of, 36

6-Mercaptopurine, pulmonary toxicity of, 39-40

Methotrexate, pulmonary toxicity of, 36-39

- and lung injury, 99-100
- clinical features, 37
- histopathology, 100-101
- incidence and mechanisms, 36-37
- pathology, 38
- prognosis, 38
- risk factors, 37

and pulmonary disease, 144-145

and rheumatoid lung, 110-111

Methylphenidate, for COPD, 475

Methylprednisolone, for ARDS, 775-776

Methylxanthines, for COPD, 366-367

Mitomycin, as cause of lung injury, histopathology, 103

- pulmonary toxicity of, 40-43
- and lung injury, 102-103
- clinical features, 41-43
- prognosis, 43
- risk factors, 42

Mononucleosis syndrome, as cause of fungal infections in lung transplant recipients, 302-303

Morphine, for dyspnea in COPD, 431

Mucokinetic agents, for COPD, 472-473

Mucolytics, for COPD, 473

Multiple organ failure, in ARDS, 581-591

- complement hypothesis and, 628-629
- definition, 581
- epidemiology, 581-583
- incidence, 582
- management, 587-588
- pathogenesis, 584-586
- prevention, 588-589, 639-641
- sepsis and, 634-635

Muscle relaxants, as cause of neuromuscular transmission impairment, 181

Myasthenia gravis, drug-induced, 181

Myoneural function, impaired, drug-induced, 180-182

Myopathies, drug-induced, 182-184

- acute painful, 182
- chronic painless, 183

Myotonia, drug-induced, 183-184

Narcotic abuse, pulmonary complications caused by, 155-156

Narcotics, for dyspnea in COPD, 431

Neocarzinostatin, pulmonary toxicity, 43

Neuroleptic malignant syndrome, 184

Neuromuscular blockade, drug-induced, treatment, 181-182

Neuromuscular blocking agents, as cause of bronchospasm, 172

Neuropathies, drug-induced, 179

Neutrophils, in ARDS, 621-622, 627-628

- role in inflammatory process associated with bleomycin-induced lung fibrosis, 26

Nifedipine, for cor pulmonale in COPD, 534-536

Nitrendipine, for cor pulmonale in COPD, 536

Nitrofurantoin, as cause of lung injury, 105

Nitrosoureas, pulmonary toxicity, 45-49

Nocardiosis, in the immunocompromised host, 59

Nonsteroidal anti-inflammatory drugs (NSAIDs), for

- ARDS, 781-782
- as cause of pulmonary disease, 146-147

Normothermic autoperfusion, for procurement of donor lungs, 220-221

NSAIDs. See Nonsteroidal anti-inflammatory drugs.

Nuclear scintigraphy, in morphologic diagnosis of drug-induced pulmonary disease, 91-92

Nutrition, in COPD, assessment, 487-494

- anthropometrics, 490-491
- body composition, 492
- body weight, 488-490
- hepatic secretory proteins, 492-493
- immunocompetence, 493
- muscle mass, 491-492
- muscle physiology, 493-494
- nitrogen balance, 492
- significance, 487-488
- support, 494-502
- calorie-protein demand, 496-498
- calorie-protein supply, 498-500
- clinical trials, 495-496
- counseling strategies, 498-499
- substrates and gas-exchange, 500-501

in early postoperative management following lung transplantation, 213, 262

in prevention of pneumonia, 650

repletion of, in COPD patients, 435-436

Occupations, as factor in COPD, 381-382

Omentum, radiologic assessment, following lung transplantation, 345

Organ failure, multiple. See *Multiple organ failure*.

Oxygen, and bleomycin therapy, pulmonary toxic reactions to, 5

- inspired, in ARDS, 756-757
- intermediate/antioxidant systems, role in bleomycin-induced lung fibrosis, 22-23
- presence of, 506
- supplemental, as factor in pulmonary sequelae following ARDS, 795-796
- supply and consumption, in ARDS, 715-722

Oxygen conserving devices, 514-516

Oxygen-cost diagram, in dyspnea, 438

Oxygen delivery, in COPD patients, 513-516

Oxygen system, for COPD patients, 511-513

Oxygen therapy, for acute respiratory failure in COPD, 508-509

- for COPD, 474-475
- establishment of baseline blood gases prior to, 508
- historical perspectives, 505
- in the home, long-term, for COPD, 505-521
- cosmetic considerations, 516
- cost considerations, 516
- during exercise, 509
- future of, 517-518
- goals, 510
- guidelines, 509-510
- Medicare reimbursement guidelines, 517-518
- multicenter trials, 506-508
- oxygen delivery, 513-516
- oxygen systems, 511-513
- portability, 516-517
- risk factors, 517
- during sleep, 509

pulmonary hemodynamics, 508

Oxygen toxicity, biochemical basis of, 73-76

- antioxidant systems, 74
- cytochrome P<sub>450</sub> system, 76
- effects of oxidants on cellular lipids, 76
- effects of oxidants on DNA, 75-76
- free radical mechanisms, 73-74
- pathology, 78-80
- physiologic manifestation of, 80-82

protein and DNA synthesis, 75  
sulphydryl oxidation, 74–75  
surfactant system, 76  
as cause of lung injury, 73–86  
pharmacologic aspects, 76–78

Oxygen transport, in ARDS, 719–720  
in COPD, 525–529

Oxygenation, extracorporeal membrane, in ARDS, 762–765  
mixed venous, in COPD, 525–529  
prone posture in, 767–768

Oxytac, for oxygen delivery, 516

Oxymizer, for oxygen delivery, 515

Papworth pulmonary preservation solution, composition of, 222

Paralysis, diaphragmatic, following lung transplantation, 288

PDO<sub>2</sub>, for oxygen delivery, 516

PEEP. See *Positive end-expiratory pressure*.

Pendant, for oxygen delivery, 515

Penicillamine, as cause of bronchiolitis obliterans, 111–112  
as cause of pulmonary disease, 139–142

Pentoxifylline, for ARDS, 783

Phlebotomy, for cor pulmonale in COPD, 539–541

Phycomycosis, in the immunocompromised host, 61

*Pneumocystis carinii* infection, following bone marrow transplantation, 325, 328  
in lung allograft recipients, 299–301  
clinical manifestations, 299–300  
diagnosis, 299  
prevalence, 299  
prevention, 287  
time course, 299  
treatment and outcome, 300–301

*Pneumocystis carinii* pneumonia, in the immunocompromised host, 61

Pneumonia, bacterial, associated with donor lung, 219–220  
following bone marrow transplantation, 324, 328  
in lung allograft recipients, 293–294  
diagnosis, 293  
pathogenesis, 294  
prevalence, 293  
treatment and outcome, 294

fungal, following bone marrow transplantation, 325  
interstitial, desquamative, drug-induced, 103–104  
lymphocytic, drug-induced, 105–106

nosocomial, in ARDS, 641–656  
bacteriology, 648–649  
diagnosis, 645–648  
incidence, 641–642  
and lung injury, 634  
mortality rate, 642  
pathogenesis, 642–645  
prevention, 649–651  
radiographic assessment, 746–747  
as factor in pulmonary sequelae following ARDS, 796–797

*Pneumocystis carinii*, following bone marrow transplantation, 325  
viral, following bone marrow transplantation, 325–326, 328

Pneumonitis, hypersensitivity, bleomycin-induced, 16–17  
gold salt-induced, 142–143

interstitial, idiopathic, following bone marrow transplantation, 327

methotrexate-induced, 99–100, 144–145  
radiation, 67–68  
diagnosis, 69

Polymyxin B, in prevention of pneumonia, 650

PortaMate and Omni, for oxygen delivery, 516

Positive end-expiratory pressure (PEEP), in ARDS, 695–697, 756–757  
cardiovascular effects, 756  
fluctuating, in ARDS, 768–769  
intermittent positive-pressure ventilation with, 703–704  
management, application of, 757

Posture, effect on dyspnea, 436

Prednisone, for COPD, 471–472  
in early postoperative management following lung transplantation, 263  
in management of lung allograft rejection, 275  
in management of lung transplant recipients, 280

Preload, left ventricular, 698–699  
right ventricular, 692–694

Procarcabazine, pulmonary toxicity, 49

Prostaglandins, for cor pulmonale in COPD, 537  
E<sub>1</sub>, for ARDS, 776–778  
in prevention of ARDS and multiple organ failure, 640

Proteinosis, alveolar, drug-induced, 106–109

Psychosocial assessment, in lung transplant applicants, 247–249

Pulmonary artery flush techniques, in procurement of donor lungs, 221–222

Pulmonary disease, antirheumatic agents as cause of, 139–150  
colchicine-induced, 147  
diffuse, differential diagnosis, in the immunocompromised host, 56  
drug-induced, evaluation, diagnostic imaging techniques, 87–94  
histopathology, 95–117  
in the immunocompromised host, 58–59  
issue on, 1–194

gold salt-induced, 142–144  
in the immunocompromised host, 55–64  
interstitial, penicillamine-associated, 142  
NSAID-induced, 146–147  
penicillamine-induced, 139–142

Pulmonary edema, ethchlorvynol abuse as cause of, 158  
following bone marrow transplantation, 326  
heroin abuse as cause of, 155–156  
salicylate-induced, 145–146

Pulmonary eosinophilia, as cause of lung injury, 104–105

Pulmonary function testing, for amiodarone pulmonary toxicity, 122–123  
in COPD, 407–410  
following heart-lung transplantation, 273  
in lung transplant recipients, 349–350

Pulmonary function tests, effect of bleomycin on, 14–16

Pulmonary heart disease, in COPD, 523–545  
circulatory pathophysiology, 524–529  
treatment, 529–539

phlebotomy, 539–541

definition, 523

Pulmonary hemodynamics, in COPD, 508

Pulmonary nodular disease, following lung transplantation, radiologic assessment, 345

Pulmonary rehabilitation, in COPD patients, 447–460, 510–511  
benefits, 448–450, 459  
components, 448  
cost-effectiveness, 450–452  
definition, 455

**Pulmonary rehabilitation (Continued)**

- limitations, 459
- role of rehabilitation team in, 448
- sequence of, 456-457
- services required for, 457-459

**Pulmonary-renal syndrome, penicillamine-associated**, 140-141

**Pulmonary toxicity, amiodarone-induced, clinical aspects**, 119-129

- mechanisms, 131-138
- bleomycin-induced, 1-20
- factors influencing, 2-6
- age, 2
- chemotherapeutic agents, 6
- dose, 2-4
- oxygen therapy, 5
- radiation therapy, 4-5
- renal function, 5-6
- route of administration, 6
- incidence, 2-3
- types, 1-17. See also specific types, e.g., *Fibrosis, interstitial, bleomycin-induced*.

of cytotoxic agents, 31-34

types, 1-2

**Pulmonary vasculature, in ARDS**, 606-612

**Pulmonary vasodilators, for COPD**, 476

**Pursed lips breathing, in COPD**, 433

**Radiation, and bleomycin therapy, pulmonary toxic reactions to**, 4

as cause of lung injury, 65-71. See also *Lung injury, radiation-induced*.

**Radiography, in ARDS**, 737-754

- in assessment of intrathoracic complications of tube placement, 748-752
- in detection of barotrauma, 747-748
- in detection of nosocomial infection, 746-747
- in distinguishing hydrostatic and increased-permeability edema, 745-746
- chest, in drug-induced pulmonary disease, 87-88
- diagnostic, in lung transplantation, 333-346
- morphologic, clinical application, 87-91
- future directions, 92-93
- nuclear scintigraphy for, 91-92

**Radiomimetic agents, as cause of lung injury, histopathology**, 95-98

**Radiomimetic injury, definition**, 95

**Rehabilitation, following lung transplantation**, 251-252, 254

**Reimplantation response, following lung transplantation**, 333-336

**Renal function. See *Kidney function*.**

**Respiration, effects of theophylline on**, 462-463

**Respiratory depression, drug-induced**, 177-179

**Respiratory failure, hypoxicemic, acute, history**, 715-716

**Respiratory muscles, adverse effects of drugs on**, 177-189

**Rheumatoid lung, drug-induced**, 110-113

**Salicylates, as cause of pulmonary disease**, 145-146

**Semustine, pulmonary toxicity**, 48

**Sepsis, in ARDS**, 576-579, 633-641

- epidemiology, 635-636
- immune factors in, 640
- and lung injury, 634-639
- pathogenesis, 636-637

**predictors of**, 637-638

**prognosis**, 638-639

**risk factors**, 636

**treatment**, 773-787

as cause of multiple organ failure, 634-635

**prevention, preformed antibodies in**, 651

**Septicemia, gram-negative, following double lung transplantation**, 232-233

**6-minute walk test, in long-term functional follow-up of lung transplant recipients**, 352-354

**Skin lesions, precancerous, cyclosporine and, following lung transplantation**, 283

**Sleep, oxygen therapy during, in COPD patients**, 509

**Smoking, cigarette, as factor in COPD**, 366, 380, 381

- as factor in pulmonary sequelae following ARDS, 795

**Socioeconomic status, as factor in COPD**, 380-381

**Stage I exercise test, in lung transplant recipients**, 354-356

**Stents, in management of anastomotic complications following lung transplantation**, 287-288

**Steroids, as cause of neuromuscular transmission impairment**, 181

**Stress, in lung transplant patients**, 248

***Strongyloides stercoralis* infection, in the immunocompromised host**, 61

**Substance abuse, pulmonary reactions**, 151-162. See also *Drug abuse*.

**Surfactant, for ARDS**, 778-780

**$\beta$ -Sympathomimetics, for COPD**, 465-469

- cardiovascular effects, 468
- dosages, 468-469
- respiratory effects, 466-467
- history, 465-466
- pharmacology, 466
- theophylline and, for COPD, 465

**$\beta_2$ -Sympathomimetics**, 425-429

**Teniposide, pulmonary toxicity**, 49

**Theophylline,  $\beta_2$ -adrenoceptor agonists and, for COPD**, 467-468

- for COPD, 426-429, 461-465, 475
- cardiovascular effects, 463
- preparation and dosages, 463-465
- respiratory effects, 462-463
- $\beta$ -sympathomimetics and, 465
- for cor pulmonale in COPD, 530
- for dyspnea, 426-429
- history, 461

**Thoracic imaging, in COPD**, 410-414

**Thoracic infections, associated with donor lung**, 219-220

**Toronto Lung Transplant Group, patient follow-up in**, 347-358

**Toxicity, pulmonary. See *Pulmonary toxicity*.**

**Toxoplasmosis, in the immunocompromised host**, 61

**Transplantation, bone marrow, pulmonary complications following**, 58, 321-332. See also *Bone marrow transplantation, pulmonary complications following*.

**heart-lung. See *Heart-lung transplantation*.**

**lung. See *Lung transplantation*.**

**Transtacheal catheters, for oxygen delivery**, 514-515

**Tremor, drug-induced**, 184

**Trimethoprim-sulfamethoxazole, for prevention of *Pneumocystis carinii* infection, following lung transplantation**, 287, 553

**Tube malposition, in ARDS, radiographic assessment**, 748-752

University of Pittsburgh experience, in pulmonary transplantation, 291-308

University of Wisconsin solution, composition of, 224

Urapidil, for cor pulmonale in COPD, 536-537

Vasculitis, drug-induced, 109-110

Vasodilators, for cor pulmonale in COPD, 532-537

    pulmonary, for COPD, 476

Ventilation, effects, on left ventricular function, 698-705

    on right ventricular function, 691-698

high-frequency, in ARDS, 765-767

intermittent negative pressure. See *Intermittent negative pressure ventilation*.

intermittent positive pressure, 702-705

inverse ratio, in ARDS, 760-762

mechanical, in ARDS, 755-772

    goals, 755-756

    conventional, in ARDS, 758-759

pressure-controlled, lung mechanics measurement in, 684

Ventricle, left, afterload, 702

    effect of ventilation on, 698-705

    function of, in ARDS, 706-709

    preload, 698-699

right, afterload, 694-698

    effect of ventilation on, 691-698

    function of, in ARDS, 705-706

    preload, 692-694

Vinblastine, pulmonary toxicity, 43-45

Vinca alkaloids, pulmonary toxicity, 43-45

Vindesine, pulmonary toxicity, 43-45

von Willebrand factor, role in endothelial cell injury, 724, 725

Water, for COPD, 472

Weight, as factor in undernutrition in COPD, 488-490

    gain in, excessive, following lung transplantation, 286